Pretty sure blafarm is just saying what Nader has said, that cancer data is far behind what was expected because patients haven't been able to go to healthcare centers to get tests done.

So this missing data will mean that BTD will be delayed and the deadline for awarding performance shares as a result of BTD will not be met.

I've wondered if those 11 million shares can be sold before the July deadline to fund the company.